Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Church & Dwight Co., Inc. (CHD) vs ClearPoint Neuro Inc (CLPT) Price & Performance

Church & Dwight Co., Inc.Trade
ClearPoint Neuro IncTrade

Price performance (Past 24H)

Key statistics

Church & Dwight Co., Inc. vs ClearPoint Neuro Inc — how do they compare? Church & Dwight Co., Inc. trades at $102.84 (market cap $24.50B), while ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M). The key difference: Church & Dwight Co., Inc. is far larger — about 55.2× ClearPoint Neuro Inc's market cap, and Church & Dwight Co., Inc. pays a 1.19% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.

CHDCLPT
Market Cap
$24.50B$444.14M
Sector
Consumer StaplesHealth
52-Week High
$105.26$29.60
52-Week Low
$81.60$8.66
Enterprise Value
$26.50B$478.72M
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Church & Dwight Co., Inc.

Church & Dwight (CHD) trades at $103.24, slightly below the consensus price target of $103.57, with a modest 24-hour decline of 0.12%. The stock exhibits a bullish technical trend, supported by moving averages, while fundamentals show steady revenue growth to $6.20 billion in 2025 and a net income margin of 11.96%. Recent Q2 2026 earnings matched estimates with organic sales growth of 5.8%, prompting raised full-year guidance. Analyst sentiment is positive with 53% buy ratings, though valuation multiples like a P/E of 33.09 suggest premium pricing.

The outlook remains favorable due to strong brand performance and raised earnings guidance, but risks include elevated debt levels and competitive pressures in consumer staples. Institutional activity shows mixed positions, with some funds reducing stakes. The stock's upside is capped by high valuations, requiring sustained earnings growth to justify current levels.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.

The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.

Returns comparison

Trailing returns across standard periods

About Church & Dwight Co., Inc.

Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.

Read more on CHD

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT